clinical trial · NCT07761572
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
Pulmonary Arterial HypertensionCS1Placebo
brief summary
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension. Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.
started
Sep 15, 2026
primary completion
Feb 2, 2029
completion
Apr 30, 2029
last updated
Aug 12, 2026
official title
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study, to Compare the Efficacy and Safety/Tolerability of CS1 Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol